97 results
Page 2 of 5
6-K
EX-99.1
uhcigz37ov41mmk
17 Nov 22
RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury
8:32am
6-K
EX-99.1
tg3utg2zzd u0jdyv
26 Oct 22
RedHill Presents New Talicia® and Movantik® Data Analyses
7:02am
424B5
lulb640uhyb8c a38g
11 May 22
Prospectus supplement for primary offering
8:47am
6-K
EX-99.1
ppruq
17 Mar 22
RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results
8:04am
6-K
EX-99.1
j31ex9k
1 Mar 22
RedHill Announces Positive Phase 2 Study Results with Oral
9:03am
6-K
EX-1.1
8f8 c5svd
22 Nov 21
Current report (foreign)
4:54pm
424B5
nzp1cph9e yr8u6z
22 Nov 21
Prospectus supplement for primary offering
4:30pm
424B5
ps8zb5d1
18 Nov 21
Prospectus supplement for primary offering
4:17pm
424B3
1apb66z 5j
9 Aug 21
Prospectus supplement
5:26pm
F-3
fd30mr do
29 Jul 21
Shelf registration (foreign)
4:31pm
F-3
EX-1.2
tbrsvdh
29 Jul 21
Shelf registration (foreign)
4:31pm
6-K
EX-1
8baf6bqv jam9
21 May 21
RedHill Biopharma Presents a New Travelers’ Diarrhea
12:28pm
424B3
44ar 8b1p17qto7c
8 Apr 21
Prospectus supplement
4:38pm
F-3
mhgi2a68q69t
30 Mar 21
Shelf registration (foreign)
8:00am
6-K
EX-1.1
iyzsg
4 Mar 21
Amended and Restated Underwriting Agreement
9:19am
424B5
qqjsw1uf
3 Mar 21
Prospectus supplement for primary offering
4:31pm
FWP
kqpgxsvpb5olfqtqc
1 Mar 21
Free writing prospectus
5:02pm
424B5
ni3ly9d
1 Mar 21
Prospectus supplement for primary offering
4:56pm